Menveo New Ready-to-Use Single Vial Presentation

Menveo is a MenACWY vaccine product approved to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W.

Menveo is now available in two presentations:

- Two-vial (requires reconstitution)
 Recommended for ages 2 months and older*
- Single-vial (ready-to-use)
 Recommended for ages 10 years and older
 NOT for use in individuals before their 10th birthday

 To extend existing stocks of MenACWY vaccine products, CDC recommends that health care providers administer specific presentations of age-appropriate vaccines. 			
Ages 2 months through 23 months	Ages 2 years through 9 years	Ages 10 years and older	
Menveo Two-vial (requires reconstitution)	Menveo Two-vial (requires reconstitution) or MenQuadfi (single-dose vial)	Menveo Single-vial (ready-to-use) or MenQuadfi (single-dose vial)	
Menactra is no longer distributed in the U	Menactra is no longer distributed in the United States; available doses will expire in October 2023.		

	 Develop a plan to add MenQuadfi to 	vour inventory if vaccinating	ng children ages 2 years through 9 years	2
П	Bovolop a plan to add mongadan to	your involvery in vaccinating	ng onliaton agos 2 yours intought o your	٥.

Important Differences Between Menveo Presentations				
Age Indications	Two-vial (vaccine + vaccine)	Single-vial (ready-to-use)		
	Ages 2 months and older	Ages 10 years and older		
Presentation Packaging	Supplied as two vials Requires reconstitution Orange cap vial contains MenA lyophilized conjugate Gray cap vial contains MenCYW-135 liquid conjugate Each carton contains 10 vials for 5 doses AND Five vials of MenA lyophilized MenCWY135 conjugate component liquid conjugate component	Supplied as one ready-to-use vial Reconsititution not required • Pink cap vial Each carton contains 10 vials for 10 doses Ten single vials of ready-to-use Menveo		
	·			
Storage	Store refrigerated between 36°F and 46°F (2°C and 8°C) Protect from light Do not freeze			
Preparation	 Reconstitution required Only use vaccine vials supplied by manufacturer Mix vaccines vials before administering See <u>Menveo</u> package inse 	Ready-to-use Reconstitution not required rt for preparation guidance		
Dosage/Route	0.5 mL/intramuscular (IM) injection Use immediately after reconstituted	0.5 mL/intramuscular (IM) injection		



* Off-label recommendations based on Advisory Committee on Immunization Practices-Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020;69 (No. RR-9):1–41. DOI: http://dx.doi.org/10.15585/mmwr.rr6909a1external icon